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Abstract
RNA interference (RNAi) is a posttranscriptional mechanism of gene regulation present
in eukaryotic cells. Inducers of RNAi are small molecules of RNA that act in the cyto‐
plasm where they are able to impair translation of a specific mRNA to protein, hence
modifying gene expression. The discovery of this mechanism in mammals led to the de‐
velopment of a new class of therapeutics with the aim of exploiting this endogenous
mechanism of action. In the last decade, great efforts have been put into understanding
RNAi and translating this accumulated knowledge into the design of modern therapeu‐
tics. With several compounds in phase III clinical development, the field is getting closer
to its first market authorization. Here we make a thorough overview of the field of RNAi
therapeutics in ophthalmology, one of the fields in which RNAi has been most successful.
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1. Introduction
Short interference RNAs (siRNA) are small molecules of double-stranded RNA of around 21
base pair long that specifically downregulate the expression of a target gene [1]. This mecha‐
nism of endogenous gene expression regulation, present in most eukaryotic cells, has been
thoroughly used to study gene function [2]. SiRNAs exert their function in the cytoplasm of
the cell, where they assemble with a several proteins to yield the RNA-induced silencing
complex (RISC), a multimeric RNA–protein complex that recognizes complementary messen‐
ger RNAs (mRNA) and promotes their degradation, thus blocking the synthesis of specific
proteins. RNAi may be activated by endogenous siRNAs synthesized in the nucleus of the cell
and generated by subsequent processing within the cell cytoplasm to yield siRNAs. Alterna‐
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tively, siRNAs can be exogenously introduced to mimic the action of endogenous RNAi
triggers [3]. Among the benefits of RNAi are the potential of transiently silencing any given
gene at any stage of development and to affect gene expression in specific anatomical regions
without affecting nontargeted regions. These benefits are being used as a basis to develop a
new class of innovative drugs that may reach the market in the next five years; the present
report highlights the advances made in RNAi therapeutics on the field of ophthalmology.
2. The special environment of the eye: advantages and disadvantages
The eye has traditionally been considered a good organ for proof-of-concept studies to assess
the efficacy of innovative therapies. It has a very particular anatomy that allows the transfor‐
mation of sensory information into electrical signals that can be thereafter interpreted by the
brain. Transformation and partial processing of sensory information takes place in the retina,
located at the back of the eye. The correct function of the eye requires light to travel through
several anatomical structures in order to reach the photosensitive retina; hence, these struc‐
tures have to be transparent or semi-transparent to allow passage of light. The environment
of the eye is extremely specialized to ensure that transparency is maintained, and there are
several mechanisms in place to ensure that this specialized environment is preserved. One of
the anatomical characteristics of the eye to allow light to travel through its structures is
restricting the blood flow to regions where transparency is not strictly required.
In addition, access to the innermost regions of the eye is controlled by several barriers; these
barriers isolate the eye from external aggressions and pathogens to but also limit the access of
therapeutics. The influence of the particular anatomical features of the eye on drug delivery is
further explained in Section 4 of this review. The barriers of the eye do not only isolate this
organ from external aggressions or substances but also limit the access of internal elements;
as such, the immune system has only limited access to the eye making the eye a partially
immune-privileged region. Finally, the aqueous humor, the clear liquid that fills the eye and
maintains its shape and pressure, has a very low content in proteins compared to serum.
Among the proteins that are significantly reduced compared to other tissues are RNases and
elements of the complement cascade. The reduced concentration of RNases increases the half-
life of RNAs used as therapeutics, and reduction in the elements of the complement cascade
further decreases the likelihood of an unwanted immune reactions to drugs.
In order to preserve its integrity, the eye has efficacious barriers to block the entrance of
pathogens and substances that could potentially affect its sensory function. The eye has
developed specific features that ensure that light travels through its tissues; this specialization
of tissues to preserve visual function is also observed by the immune system [4]. Immune
responses change the local environment of tissues and are frequently associated to tissue
inflammation. In order to avoid these potentially harmful changes, the eye has a relatively
immune privileged status. This immune privilege status is maintained by several mechanisms.
Absence of lymphatic and blood vessels in certain areas and abundance of immunosuppressive
factors in the aqueous humor are among these mechanisms [5]. On the other hand, the eye
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needs to be able to respond to situations in which its integrity can be compromised such as
viral or bacterial infections. The innate immune response is the first system activated in
response to aggressions; it acts like a watchdog mechanism recognizing pathogen-associated
molecular patterns (PAMP). Depending on the molecular characteristics and location of the
PAMP, different effectors of the innate response are activated; these responses can be mediated
by toll-like receptors (TLR) or independent of these receptors. Toll-like receptors discriminate
self-motifs from non-self-motifs [6]. There are ten known TLRs, and they differ in their
subcellular localization and in the type of non-self-pattern they recognize. TLR1, TLR2, TLR4,
TLR5, and TLR6 recognize components of bacterial walls and are located in the cell surface,
whereas TLR3, TLR7, TLR8, and TLR9 recognize oligonucleotides and are sequestered in
intracellular compartment. TLR3 binds to single- and double-stranded RNA, TLR7 binds to
single-stranded RNA, and TLR9 binds to unmethylated CpG motifs, usually found in bacterial
DNA. In the eye, the expression pattern of each TLRs varies depending on the anatomical
structure; all TLRs are present in the corneal and retinal pigment epithelia; TLR4 is the
predominant TLR in the rest of the eye structures where it localizes in resident antigen
presenting cells [7, 8]. TLR-independent response mechanisms to cytoplasmic oligonucleotides
include dsRNA-binding protein kinase, the RNA helicase (RIG-I), and oligoadenylate synthase
enzyme. These proteins are cytoplasmic dsRNA sensors belonging to the antiviral innate
immune system, which plays an important role in antiviral defense in response to viral
infection and replication [9].
The first proof-of-concept studies to demonstrate the viability of silencing genes in the eye
showed that the injection of siRNAs into the subretinal space or vitreous cavity could indeed
downregulate specific genes. In these experiments, the downregulation of genes of the vascular
endothelial growth factor (VEGF) family with siRNAs correlated with the inhibition of ocular
neovascularization [10, 11]. The first set of these experiments used an adenoviral vector that
codified for an siRNA designed against VEGF1. The subretinal injection of this vector 36 h after
the induction of coroidal neovascularization (CNV) by laser reduced the areas of neovascula‐
rization compared to areas of mice injected with vector codifying for a scrambled siRNA [10].
In a subsequent study, Campochiaro and coworkers [10] demonstrated that the inhibition of
ocular neovascularization could also be achieved by injecting a VEGFR1 siRNA directly,
without an expression vector, into the vitreous cavity. The siRNA used in this study had the
so-called canonical design, which comprises a 21-nucleotide guide strand and a complemen‐
tary passenger strand annealed to form an siRNA duplex with a 19-bp dsRNA stem and 2
nucleotide 3′ overhangs at both ends [11].
In 2008, Kleinman and coworkers published a study in Nature demonstrating that the effect
of siRNAs on CNV was mediated by activation of TLR3 rather than an effect on target [12].
The  results  of  these  studies  showed  that  the  effect  of  the  siRNAs  on  CNV  was  dose-
dependent but not dependent on sequence. In addition, the authors demonstrated that a
minimum length of the siRNA was required in order for the molecules to have an effect
on CNV; this length was show to be at least 21 nucleotides. The study also showed that
the internalization of the siRNAs was not required for the inhibition of CNV as cells of the
retinal pigment epithelium (RPE) abundantly express TLR3 on the cytoplasmic surface. The
authors  used  several  sequences  to  point  out  that  the  inhibition  of  CNV  was  mediated
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through an off-target  effect.  Using docking models,  the  authors  showed that  TLR3 and
siRNAs were indeed able to interact with each other but the interaction was unstable when
siRNAs were shorter than 21 nucleotides. A subsequent study by the same group showed
that activation of TLR3 by IVT siRNAs led to caspase-3-mediated degeneration of the RPE
questioning the safety these compounds as therapeutics for back of the eye diseases [13].
The findings of Kleinman and coworkers boosted research on alternative designs that could
successfully  block  immune  recognition;  among  the  most  commonly  used  strategies  are
incorporation of delivery systems and 2’-ribose modifications.
Finally, exogenous RNAs are quickly degraded by RNases present in tissues and body fluids
[14]. These enzymes cut RNA into smaller components that are subsequently incorporated into
the route of degradation of nucleotides. RNAses are present at high concentrations both in
tissues, such as in spleen, liver, and pancreas, and in biological fluids, such as in serum [15].
In the eye, the tear fluid is rich in nucleases but the presence of these enzymes is considerably
lower in most eye tissues, thus allowing for increased half-life of the siRNAs used for thera‐
peutic purposes.
3. Efficacy studies: Animal models to study the eye
Proof-of-concept studies are required in order to demonstrate that a particular drug has the
proposed activity. siRNAs are designed using bioinformatics tools to target specific regions of
the human genome. Therefore, assessing the activity of these molecules in animal models
requires that the siRNA has biological activity in the species chosen to perform the proof-of-
concept study. With the sequencing of the genome of most animal models used in biomedical
research, evaluating the homology of a given sequence between two species is nowadays
common practice, but this does not warrant finding a fully homologous siRNA for all targeted
genes. In cases where homologous sequences cannot be found, a surrogate compound can be
used to perform animal efficacy studies; this entails designing a compound that targets the
exact same region as the human version but with the sequence of the gene of the animal species
to be used. Several animal models can be used to assess the activity of a compound. Here we
highlighted the animal models used in the developmental programs of products included in
the ophthalmic siRNA pipeline.
3.1. Ischemic optic neuropathy
Ischemic optic neuropathy is a sudden loss of vision caused by interruption or decreased blood
flow in the optic nerve. There is a disagreement as to its pathogenesis, clinical features, and
management because ischemic optic neuropathy is not a unique disease, but a spectrum of
different types [16]. Ischemic optic neuropathy can be primarily of two types: anterior (AION)
caused by the interruption of blood flow in the optic nerve head and posterior (PION)
involving the posterior part the optic nerve. Both types can be further classified into different
subtypes. AION comprises arteritic (A-AION) caused by giant cell arteritis and nonarteritic
(NA-AION) caused by other than giant cell arteritis. NA-AION is by far the most common
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type and typically affects individuals between 55 and 67 years of age. The incidence of AION
has only been thoroughly studied in the USA where there are 2.3–10.3 cases per 100,000
inhabitants; for the nonarteritic type, the numbers are lower: 0.36 per 100,000 inhabitants. NA-
AION is characterized by visual loss, optic disc swelling, sometimes with flame hemorrhages
on the swollen disc or nearby neuroretinal layer, and sometimes with nearby cotton wool
exudates. Visual loss is usually sudden and may progress over several hours to days and even
weeks [17].
Animal modes of this disease are used to assess efficacy of pharmaceuticals in development
for these conditions and include the optic nerve crush model and the photoembolic stroke
model. The optic nerve crush model is a general model in which surviving of the ganglionar
cells can be studied in response to a physical damage to the optic nerve [18]. In the photoem‐
bolic stroke model, a photosensitive dye, such as rose bengal, is injected intravenously, and
laser is specifically applied to the optic nerve head to activate the dye. The activation of the
dye results in damage to the endothelial cells of the optic nerve vascular system that ultimately
leads to thrombosis of vessels and edema of the optic nerve head [19].
3.2. Glaucoma
Glaucoma is  a  group of  progressive  optic  neuropathies  characterized  by  vision  impair‐
ment  and degeneration of  retinal  ganglion cells  that  if  left  untreated can lead to  blind‐
ness. Glaucoma is the second leading cause of global irreversible blindness, and it has been
estimated that 60.5 million people were affected by primary open-angle glaucoma (POAG)
and  primary  angle–closure  glaucoma  (PACG)  globally  in  2010,  a  number  expected  to
increase to nearly 80 million by 2020 [20]. The degeneration of the optic nerve is thought
to be produced as a result of changes in intraocular pressure (IOP), but specific molecu‐
lar  mediators  of  these  changes  have  yet  to  be  identified.  Because  glaucoma  may  be
asymptomatic until a relatively late stage where the nerve damage has already occurred,
early diagnosis and treatment are crucial for halting the progression of the condition [21].
Reduction  of  IOP is  the  only  proven  strategy  to  treat  the  disease;  thus,  first-line  treat‐
ments are aimed toward achieving this goal. There are several compounds currently used
to lower IOP, and although most of them are efficacious in lowering IOP, they all come
with their  own set  of  side effects  and tolerance to  the drug is  a  frequent  phenomenon.
Tolerance or reduced response of  the drug requires change of  drug regimen, frequently
increasing the dose or combining the prescribed pharmaceutical with another drug [22, 23].
Depending on the specific phase of the disease one wants to model, several animal models can
be used [24]. If studying the degeneration of the retina is the main objective, the models
mentioned in the previous section can be used. For assessing the IOP lowering efficacy of
pharmaceuticals, models with increased IOP are generally used. The increased IOP model
induced by oral water overloading in rabbits is a very easy and physiologic model to screen
compounds. The basis behind this model is to give the animal an oral overload of water that
will result in a transient increase in IOP [25]. Although the specific mechanism behind the
increase in IOP following water overloading is uncertain, the model has been extensively used
to perform rapid screens of IOP-lowering compounds. The main advantage of this model over
other existing models of increased IOP is that the anatomical structure and physiology of eye
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structures are preserved allowing a normal response to hypotensive drugs. Other models of
increased IOP include laser photocoagulation, intracameral injection of latex microspheres,
topical application of prednisolone, light-induced reduced outflow facility, subconjunctival
injection of betamethasone, or episcleral vein occlusion [24].
3.3. Dry eye disease
Dry eye disease (DED) is a multifactorial disease of the tear-fluid and ocular surface that results
in symptoms of discomfort, visual disturbance, and tear film instability. It is accompanied by
increased osmolarity of the tear film and inflammation of the ocular surface [26]. Common
symptoms of this condition include blurry vision, tearing, and ocular pain. There are several
factors that contribute to the etiology of the disease, among them are insufficient tear secretion,
excessive evaporation, and alteration in the composition of the tear film [27]. Temporary
changes of the composition of the tear film can cause an acute form of DED; if changes persist,
the condition can turn into chronic DED. Damage to the ocular surface is usually more severe
in the chronic forms than in the acute types. DED is frequently associated to other conditions
such as Sjögren’s disease or lachrymal gland dysfunction, but it can also be caused by vitamin
deficiency, contact lens wear, and use of several prescription drugs. Acute DED is handled
with lubricants and avoiding preservatives in concomitant eye drops. If DED persists,
treatment options include procedures that favor tear retention such as punctal occlusion,
moisture chamber spectacles, contact lenses, or pharmacologic agents that stimulate tear
secretion. More severe forms may require the use of anti-inflammatory therapy [28]. Although
some advances have been made toward alleviating some of the symptoms of DED, pain
associated to this condition is not usually addressed. Pain in the eye results from stimulation
of sensory axons of the trigeminal ganglion neurons innervating the cornea [29]. Animal
models to assess the efficacy of ocular analgesics are extremely complex in terms of interpreting
efficacy outcomes [30]. One of the commonly used models to study pain is the capsaicin-
induced ocular pain model developed by Gertrudis and colleagues [31]. This model is based
on the evaluation of animal behavior after topical ocular administration of capsaicin, a selective
agonist of transient receptor protein vaniloid type 1 (TRPV1). Capsaicin applied locally to the
eye activates TRPV1 inducing palpebral closure. Latency to open the eye and time required
for complete palpebral opening can be used as measurements of the discomfort caused by
capsaicin. Reference products used in this model include analgesics, in particular, capsazepine,
the antagonist of TRPV1 channels.
3.4. Ocular allergy
Ocular allergies constitute a heterogenic group of diseases with a broad spectrum of clinical
manifestations and include mild forms such as seasonal allergic conjunctivitis (SAC) and
perennial allergic conjunctivitis (PAC), and more severe manifestations such as vernal
keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjuncti‐
vitis (GPC). The severe forms can be associated to complications such as corneal damage and
may cause vision loss. SAC and PAC are commonly IgE-mast cell-mediated hypersensitivity
reaction to external allergens, whereas AKC and VKC are characterized by chronic inflamma‐
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tion involving several immune cell types. In SAC and PAC, allergens, with the help of antigen
presenting cells, trigger a Th2-predominant immune response that induces B cells to release
IgE. In SAC and PAC, allergen-induced local release of IgE prompts infiltration and degranu‐
lation of mast cells in Ca2+-dependent mechanism. Mast cells liberate preformed inflammatory
mediators such as histamine and leukotriene 4 that subsequently attract eosinophils amplify
the allergic response [32]. The prevalence of ocular allergies in the general population is
estimated to be around 40% in the United States [33] and up to 35% in Europe and the Middle
East [34], but it is probably underestimated in most epidemiologic studies [35]. The primary
treatment for ocular allergies includes avoidance of allergens, cold compresses, and lubrica‐
tion. In persisting cases, symptoms can be treated using topical and oral decongestants,
antihistamines, mast-cell stabilizers, or anti-inflammatory agents [36]. Allergic conjunctivitis
can be modeled in animals by exposing them to allergens in the presence of an adjuvant [37].
The model developed by Magone and coworkers uses Female Balb/C mice that are sensitized
with short ragweed and alum and several days later animals receive a topical dose of short
ragweed pollen in the eye. A prescreening of mice can be performed in order to select only
those animals that respond to allergens.
3.5. Age-related macular degeneration with choroidal neovascularization
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in indi‐
viduals over 50 years of age [38, 39]. AMD is caused by a combination of genetic and environ‐
mental factors. Risk factors include hypertension, cardiovascular disease, smoking, and high
BMI. Among the genetic factors that confer susceptibility to developing AMD are variants in
genes encoding complement pathway proteins [40, 41].
The underlying cause for AMD is accumulation of drusen or residual material produced by the
renewal process of the external part of the photoreceptors of the retina in the retinal pigment
epithelium (RPE). The accumulation of this material in the RPE leads to the production of
inflammatory mediators that cause photoreceptor degeneration in the macula and severe vision
loss [42]. In the early stages of the disease, accumulated drusen are small; the size and amount
of this material increase as the disease progresses and central vision deteriorates.
There are two types of AMD: dry or wet. Dry AMD is characterized by the degeneration of the
RPE and photoreceptors along with changes in pigmentation of the RPE. In the wet form, or
choroidal neovascularization (CNV), fragile blood vessels of the choriocapillaris grow into the
RPE and frequently leak blood and fluid that accumulate between RPE and choriocapillaris.
As a result of these abnormal growths, dense scars are formed in the macula, and the RPE can
detach. The wet form is more severe than the dry form and sometimes dry AMD can develop
into wet AMD [43].
The characteristic invasion of leaky blood to the RPE in wet AMD is mediated by VEGF. The
discovery of the relationship between VEGF and changes in vasculature in AMD led to the
development of different approaches aimed to decrease the levels of this growth factor.
Antibodies targeting VEGF are currently the first-line treatment for wet AMD [44]. The
hallmark of wet AMD is CNV; thus, this is the lesion most extensively modeled in animals to
assess efficacy of compounds targeting this disease. The laser-induced CNV model is by far
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the most used animal model. This model, initially developed for nonhuman primates (NHP),
was later adapted into rodents. The basis for this model is to induce a break in Bruch’s
membrane using a high-energy laser. The experimental CNV can be analyzed in vivo using
fluorescein angiography or optical coherence tomography or postmortem studying the retina
explants. The model has been successfully transferred and validated to rat and mouse, and in
both species, the chain of events taking place after lesion induction resembles the events that
tale place in humans with the disease. Other models include the injection of subretinal
materials such as Matrigel, angiogenic substances, macrophages, lipid peroxides, or polyethy‐
lene glycol. Although these models are promising, they have yet to be appropriately validated
in order to be used as a proof of concept tools [45].
3.6. Diabetic retinopathy
Diabetic retinopathy (DR) is an ocular complication of diabetes mellitus characterized by
microaneurysms in the retinal vasculature that eventually lead to ischemia and macular
edema. Changes in the retina can cause rapid vision loss, and this complication is the main
cause of visual loss in working-age individuals [46, 47].
The initial phase of DR, known as nonproliferative DR, is characterized by the thickening of the
capillary basement membrane and apoptosis and migration of pericytes. These microchanges
cause microaneurysms and small leakages in the vessels that irrigate the retina. As the disease
progresses, interaction between endothelial cells and pericytes weakens and the capillaries
become permeable; subsequent accumulation of fluids in the macula leads to edema. The
microaneurysms in the retinal capillaries cause occlusions that compromise blood flow through
the  retina  and  cause  ischemia.  Local  hypoxia  upregulates  angiogenic  factors  that  cause
capillaries to grow into the retina,  preretinal space,  and vitreous cavity;  stage known as
proliferative DR [48]. Among the upregulated angiogenic factors, one of the most critical is
VEGF; the newly formed vessels are structurally deficient and very responsive to this growth
factor. As such, antibodies used to treat AMD are also used for the treatment of diabetic
retinopathy. DR is usually treated with laser photocoagulation, a procedure that does not cure
the disease but mitigates the damage. IVT steroids can also be used to reduce accumulation of
fluids within the retina. If accumulation of blood in the vitreous humor physically impedes laser
photocoagulation, a vitrectomy has to be performed in order to remove the blood accumulat‐
ed in the vitreous prior to laser photocoagulation.
There are several animal models of diabetic retinopathy, each of them comes with its own set
of advantages and disadvantages. One of the most extensively used is the streptozotocin (STZ)-
induced diabetes model. Intravenous or intraperitoneal injection of STZ causes a rapid and
selective destruction of β-pancreatic cells leading to hyperglycemia and development of type I
diabetes. The model has been used successfully in several animal species including rat, mouse,
rabbit, dog, and monkey. Nonproliferative DR develops in this model, but microaneurysms
and neovascularization are seldom observed; hence, this model can be complemented with the
laser-induced CNV model explained in the AMD section. Larger animal models can be generated
by surgically removing the pancreas, but this model is significantly more complicated to
generate than the STZ model and has the same drawbacks. Alternatively, animals can be fed a
high-galactose diet, but the induction of diabetes is considerably slower [50].
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4. Biodistribution studies
Despite the extraordinary potential that RNAi technology displays in the treatment of ocular
conditions, the transition of siRNAs programs to the clinical setting still presents challenges.
The in vivo efficacy of therapies based on siRNAs depends on the ability of a given siRNA to
reach the cytoplasm of its target cell in sufficient quantities to achieve its desired biological
effect. The intrinsic characteristics of siRNAs such as their sensitivity to degradation by
endogenous enzymes, their relative large size, and its negative charge limit their ability to cross
biological barriers and reach the cytoplasm. Approaches used to overcome the hurdles
associated to the use of siRNAs range from delivery strategies to chemical modifications aimed
towards improving the pharmacological properties of the therapeutic siRNAs.
Drug delivery into the eye is challenging due to the presence of static and dynamics barriers
that protect the internal tissues. The eye consists of two anatomically differentiated regions:
the anterior and posterior segments. The anterior segment includes the cornea, conjunctiva,
iris, ciliary body, lens, and anterior and posterior chambers; this segment occupies approxi‐
mately the anterior third of the eyeball. The posterior segment is of greater size and comprises
the sclera, choroid, retina, and vitreous cavity. There are significant anatomical, molecular,
and immune differences between the two segments; thus, strategies to deliver molecules to
the eye will be very different depending on the targeted segment [51]. The anterior region of
the eye is protected from exterior aggressions by the cornea and tear film. The former is a
specialized tissue composed of five layers that constitutes the main physical barrier to external
molecules; the latter is an enzyme-rich fluid that degrades many biological molecules,
lubricates the eye surface, and washes away materials from the cornea. In addition, many
components of the tear film impede adhesion of molecules to the eye surface further restricting
the access of external molecules to the inside of the eye.
Topical ocular administration of drugs is a patient-friendly administration route typically used
for the treatment of pathologies affecting the anterior segment of the eye. However, molecules
applied as eye drops are quickly cleared from the ocular surface being the bioavailability of a
compound administered via this route less than 5% of the initially applied dose. The standard
volume of a commercial eye drop is approximately 40 µL whereas the normal volume of the
tear fluid in the ocular surface is 7-9 µl. Once an eye drop is instilled in the inferior conjunctival
sac, there is a transient increase of volume that activates the blinking reflex and increases the
turnover of the tear film. Most of the content of the eye drop is spilled out by the blinking
process or drained via the nasolacrimal duct, drastically reducing the amount of compound
available to the eye.
The cornea is a specialized tissue covering the anterior part of the eye whose main functions
are protecting against harmful agents and provide the eye with a refractive surface that allows
the entrance of light. The human cornea is approximately 0.5–0.8 mm thick, and it is comprised
of three layers: the outer five cell layer-epithelium, a thick stroma rich in type I collagen fibrils
and glycosaminoglycans, and the innermost endothelium consisting in a single layer of
cuboidal cells. The corneal epithelium is separated from the stroma by the Bowman´s mem‐
brane, while the stroma and the corneal endothelium are separated by the Descemet´s
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membrane. There are no blood vessels irrigating the cornea; this provides the required
transparency for the transmission and refraction of light. Drugs can take two paths to penetrate
the corneal epithelium: the intracellular path crossing through the cells or the paracellular path
bypassing between cells. The cells of the corneal epithelium are tightly attached to each other
with gap and tight junctions that restrict the diffusion of large molecules between them [52–
54]. The cross-cellular pathway requires molecules to be able to cross cell membranes; thus,
lipophilic molecules have an easier access through this route. The stroma is an aqueous matrix
composed mainly of hydrated collagen and proteoglycans with few keratinocytes interspersed
[55]. The hydophilicity/lipophilicity index determines the diffusion of molecules through this
layer [56]. The remaining layers of the cornea do not significantly hamper the diffusion of
molecules.
Contrary to the cornea, the conjunctiva is a highly vasculated tissue that covers the sclera and
lines the inner surface of the eyelids. Its main functions are producing mucus and tears to
lubricate the eye surface and preventing the entrance of pathogens. The human conjunctiva is
composed of three layers: the outer epithelium, the substantia propia, containing nerves and
blood vessels, and the submucosa layer, which provides a lightweight attachment to the
underlying sclera [57]. The histology of the stratified outer epithelium varies among the different
regions of the conjunctiva, but it is always its apical portion that controls the permeability of
the conjunctiva. The conjunctiva offers an attractive route for drug delivery when compared to
the cornea as it presents an extended exchange surface as well as a superior rate of permea‐
tion to large hydrophilic molecules. The sclera is structurally continuous with the cornea and
extends posteriorly from the limbus. The composition of the sclera is similar to that of the corneal
stroma, mainly collagen and mucopolysaccharides leaving numerous channels through which
drugs can freely diffuse [58]. The sclera is poorly vascularized and significantly more permea‐
ble than the cornea but less permeable than conjunctiva. There are contradictory reports on the
ability of charged molecules to cross the sclera. Some authors suggest that this layer is more
permeable  to  negatively  charged molecules  [59,  60],  whereas  other  studies  suggest  that
positively charged molecules  cross  the sclera more easily  [61,  62].  Ranta and colleagues
suggested that the negative charge of mucopolysaccharides in the sclera prevented the diffusion
of negatively charged molecules as a consequence of charge repulsion. Other studies have shown
that negatively charged molecules are indeed able to cross the sclera, pointing out that size is
the limiting factor in drug diffusion through this layer [52]. It should be noted, however, that
scleral drug binding does not necessarily impair drug delivery to inner structures of the eye; it
can also act as a drug-depot if the molecules are subsequently released [63].
Ophthalmic drugs topically administered to de eye can thus be absorbed through two
pathways: crossing the cornea to reach the aqueous humor or through the conjunctival-scleral
pathway reaching the uvea. The relative quantity that enters through each of the above-
mentioned routes varies significantly depending on the size and hydrophilic/lipophilic ratio
of the molecule. Generally, the conjunctival route is favored for large hydrophilic molecules,
whereas small lipophilic drugs are mainly absorbed through the cornea. The ability of siRNAs
to penetrate the cornea has been thoroughly demonstrated as well as the ability of these
compounds to enter the cytoplasm of cells within the cornea. However, the capacity of siRNAs
to cross the cornea is limited, as shown by the limited amount of siRNAs detected in the
aqueous humor following eye drop instillation [64].
RNA Interference254
Increasing the amount of compound in the anterior part may be of interest for treating specific
conditions. For this purpose, several strategies can be used in order to improve delivery: (a)
increasing the residence time of the compound within the eye surface, (b) directing the
molecule to a specific region to increase the concentration locally, and (c) increasing absorption
by using physical methods. Increasing the contact time of the molecule with the eye surface
can be achieved by the use of formulations or depots. Formulations that increase viscosity and/
or mucoadhesion of ophthalmic solutions are generally believed to increase absorption into
the eye. Polymers such as methylcellulose or polyvinyl alcohol can be added to solutions to
increase viscosity and consequently increase residence and reduce clearance time. Mucoad‐
hesion may be increased by formulating the oligonucleotides in polymers such as chitosans.
These polymers have been used to deliver DNA vectors into the eye [65]. Encapsulation in
liposomes and in thermosensitive gels has also been attempted as a means to increase the
absorption and residence time of oligonucleotides in the eye [53]. In these studies, a 16-mer
was formulated in liposomes, a thermosensitve 27% poloxamer gel, and HEPES; the results of
these studies showed that the amount of compound reaching external tissues such as the
conjunctiva or the cornea was higher when the compound was prepared in HEPES. By contrast,
access to deeper regions of the anterior chamber such as the sclera or the iris benefited from
the increased viscosity of the gel formulation [53]. One of the main drawbacks of biodistribu‐
tion studies to assess the fate of a given siRNA in a formulation is that most of these studies
focus on the fate of nanocarrier rather than on that of the oligonucleotide and the relative
distribution of the molecule among the tissues of the eye. Therefore, thorough biodistribution,
studies are required to address the specific characteristics required for improving delivery for
specific conditions. Targeting has scarcely been used to deliver oligonucleotides into the eye;
there are a few reports using dendrimers with the goal of increasing the intracellular concen‐
tration of therapeutic oligonucleotides in specific regions of the eye, but advances toward this
goal are as of today very limited [66]. Physical methods such as iontophoresis have also been
studied aiming to increasing the amount of molecule that crosses the cornea and/or the sclera.
Although iontophoresis certainly increases the amount of transcorneal and transcleral delivery
of oligonucleotides mainly to the anterior chamber but also to some degree to the posterior
chamber, the use of this method has not been extensively used most likely because the
equipment required to apply the required current would entail in-office administration, which
would significantly complicate repeated administrations [67].
Drugs administered systemically enter the eye from the bloodstream crossing the capillaries
of the choroid. The choroid is a vascular layer composed of capillaries and supported by
Bruch’s membrane, a connective membrane of 2–4 µm thickness. Bruch’s membrane separates
the choroid from the retina, forming the main barrier to permeation across the choroid-Bruch’s
bilayer [68]. The permeability of Bruch’s membrane is relatively high; charge and size do not
generally affect drug diffusion through this membrane unless molecules are very big; in this
particular case, size can reduce the rate of permeation [52]. The choroid is a thin and permeable
membrane that is rich in melanin. Melanin has the ability to bind and retain many drugs
hampering their entrance to the retina and inner tissues. Other drug-binding proteins,
depending on the kinetic of binding/unbinding retention of drugs by melanin, can completely
block the entrance or act as a reservoir for slow release [69]. Studies to assess the binding of
oligonucleotides to melanin have yielded different results suggesting that at least some
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oligonucleotides bind to melanin reducing the rate of entrance to the retina; this is however
not the case for all oligonucleotides [52, 70].
The main restriction to free permeation of molecules from systemic circulation to the eye is the
blood–retinal barrier (BRB). The BRB is composed of the inner BRB and the outer BRB. The
former includes the vessels of the retina, whereas the latter is constituted by the retinal pigment
epithelium (RPE). Both barriers possess cells with well-developed intercellular junctions that
control the permeation of substances through them. Larger molecules, such as proteins and
nucleic acids, are mostly able to permeate through the choroid but have limited ability to cross
the inner BRB; thus, drugs need to exit the choroid and penetrate the eye crossing the outer
BRB. Crossing through the outer BRB usually requires high systemic doses increasing the
likelihood of systemic side effects [71]. Delivery to the posterior segment of systemic or
topically applied drugs requires thus crossing several biological barriers. Therefore, invasive
administration procedures are frequently used to deliver drugs to the posterior segment. In
addition, the outflow mechanisms of the eye rapidly remove drugs from the posterior chamber;
thus, reaching clinically meaningful concentrations is challenging. Most of the programs
developing siRNAs for eye conditions target the back of the eye; consequently, the route of
administration is IVT injection. The concentration of siRNAs administered IVT is highest in
the vitreous body, but they are also found in the RPE, choroid, and retina. Depending on the
stability of the siRNAs, the compound can also be found in systemic circulation.
There are numerous reports describing strategies that can be of benefit for increasing the
concentration of drugs in the back of the eye. Several nonbiodegradable (Retisert™, Illuvien™,
and Vitrasert®) and one biodegradable (Ozurdex™) intravitreal ocular inserts are currently
used in the clinical practice for delivering small molecules to the back of the eye. It is expected
that these advances be soon incorporated into the pipelines of larger molecules such as proteins
and oligonucleotides.
5. Toxicology
siRNAs are chemically synthesized oligonucleotides and are considered New Chemical
Entities (NCEs) by the US and European Regulatory Authorities since 2009 when the European
Commission excluded siRNAs from the definition of advanced medicinal products [72].
Toxicology assessment of RNAi-based drugs should be carried out following guidelines for
NCEs, and the complete toxicology battery is usually performed following the recommenda‐
tions of the ICH M3 (R2) guideline [73]. The guideline recommends the assessment of toxicol‐
ogy in two species, a rodent and a nonrodent, at three dose levels and for a duration that should
be similar or superior to the clinical trial to be carried out. This assessment should include
acute or maximum tolerated toxicology studies and repeated-dose toxicity studies. Addition‐
ally, pharmacokinetics, safety pharmacology, genotoxicity, carcinogenicity, and specific
toxicology studies should be carried out depending of the nature, indication, and route of
administration of the product. On the other hand, some aspects of RNAi-based products are
closer to new biological entities (NBEs) rather than NCEs; therefore, some of the requirements
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of the ICH S6 guideline also apply to the design of their developmental programs [74]. As such,
a tailored toxicology assessment program should be designed combining the recommenda‐
tions outlined in the above-mentioned guidelines and the accumulated experience of numer‐
ous compounds tested in preclinical and clinical development.
Toxicology of ocular products depends on their biodistribution and on their biological activity.
Moreover, the disease process, age, sex, or eye pigmentation are other potential factors
affecting the toxicity profile of the ocular drug assessed. Additionally, the bioavailability of
the RNAi compound will depend mainly on the route of ocular administration (topical versus
injected) and on the physicochemical characteristics of the drug.
Toxicities arising from oligonucleotides, including siRNAs, can be classified into hybridiza‐
tion-dependent toxicities and hybridization-independent toxicities. Hybridization-dependent
toxicities can be caused by (a) exaggerated pharmacology: excessive activity on the intended
target or by (b) off-target effect: modulating gene expression of an unintended target by an
RNAi-mediated mechanism. Hybridization-independent toxicities are often associated to the
chemistry of the siRNA. Identified hybridization-independent toxicities include prolongation
of activating partial thromboplastin time (aPTT), complement activation, and immunostimu‐
lation [75, 76, 77].
5.1. General toxicology
Up to date, numerous siRNAs indicated for different eye conditions have entered clinical trials
(Table 1); the administration route of four of these compounds is by IVT injection, whereas the
remaining two compounds are topically administered in eye drops. The toxicology assessment
of these products follows the traditional schedule for NCEs; this schedule entails general
toxicology studies in two species, a rodent and a nonrodent species of variable length. Most
programs up to date have used NHP as the nonrodent species; this is because siRNAs are
species specific, and it is likely that the assessment of toxicology was performed in the only
species in which the compound was pharmacologically active. The rabbit is very frequently
used to assess toxicology of compounds under development for eye conditions. Many sponsors
of programs using NHP or dog as nonrodent species chose to use the rabbit as second species,
although this animal is not a rodent per se. Reasons behind this choice include the similarity
of the volume of the eye to that of humans and the difficulty of administering controlled doses
to smaller animals. This is particularly relevant when the compound is administered by IVT
injection. This rationale has also been followed for developing siRNAs for eye conditions; only
in one case, PF-04523655, rats were used as the rodent species, and the rest of the programs
developing siRNAs for eye indications used the rabbit (New Zealand White rabbits or Dutch
Belted rabbit) as second species for toxicology assessment.
Most programs developing siRNAs for eye conditions include acute/maximum tolerated dose
and repeat-dose toxicology studies. The length of these studies is determined by the indication,
stage of development, and envisioned duration of treatment. In addition, most programs do
not only perform toxicology studies using the envisaged route of administration but also
include studies using intravenous route to challenge the systemic exposure to the drug and
assess potential dose limitations and target organs.
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5.2. Genotoxicity
As mentioned in the previous section, both the ICH M3 (R2) and the ICH S6 guidelines apply
to programs developing siRNAs [73]. The ICH S6 states that the range and type of genotoxicity
studies routinely conducted for NCEs are usually not applicable to NBEs; pointing out that
performance of these studies is only required when there is a cause of concern. The European
Medicines Agency (EMA) issued a reflection paper on the assessment of the genotoxic potential
of antisense oligodeoxynucleotides in January 2005. This paper recommends addressing at
least two issues in regards to oligonucleotides which may indicate a cause of genotoxic concern:
(a) analyzing the potential of incorporation of phosphorothioated (PS) oligonucleotides into
the DNA and (b) addressing the potential of triplex formation of oligonucleotides with the
DNA fiber [78]. Several years of experience with siRNAs indicate that full-length molecules
are very unlikely to interact with the DNA. Thus, the potential cause of concern may arise from
the genotoxic potential of metabolites or chemical contaminants. The metabolism of nonmo‐
dified oligonucleotides yields naturally occurring nucleotides that are subsequently incorpo‐
rated to the natural degradation pathways of endogenous nucleic acids; thus, toxicities derived
from these degradation products are not expected. Modified oligonucleotides, on the other
hand, incorporate very frequently backbone modifications to reduce nuclease activity and
improve other pharmaceutical properties of the molecule. The most commonly used backbone
modification is the replacement of a nonbridging oxygen on the backbone between two
ribonucleotides with a sulfur to create a PS linkage [79]. Extensive genotoxicity studies
performed with Vitravene, a PS antisense oligonucleotide administered by IVT injection,
indicate that oligonucleotides with a PS backbone do not pose genotoxic potential [80, 81].
These results are in line with those obtained in the analysis of over 30 compounds studied in
the standard battery, all of which have yielded negative results. Other modified nucleotides
could potentially be incorporated into nucleotide pools and be thereafter used to synthesize
DNA. The standard battery of tests would detect eventual damaging potential of theses
degradation products.
The EMA reflection paper also recommends assessing the potential of triplex formation with
the DNA fiber. For this to happen, siRNA molecules would have to enter the nucleus of the
cell and their structure should include an uninterrupted homopurine stretch of at least 10–12
base pairs that should be homologous a given region of the DNA. In silico design of siRNAs
usually addresses these issues and candidates with the ability of forming triplex are avoided
prior to lead selection.
5.3. Carcinogenicity
Standard carcinogenicity studies are generally not required for NBEs, but these studies may
be required for siRNAs depending on their chemical structure, clinical dosing, patient
population, or biological activity. If the in vitro test genotoxic studies indicate that there is
cause of concern for carcinogenic potential, further studies should be required in relevant
models.
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For RNAi products under development for eye conditions, the systemic bioavailability of these
products is usually very low, and a waiver to perform these studies may be justified. Strategies
should be discussed in a case-by-case base with the competent health authorities.
5.4. Reproductive and developmental toxicity
The assessment of reproductive and developmental toxicity is required to support the use of
a given pharmaceutical in pregnant women, women of childbearing potential, or children.
These studies are regulated by the ICH S5 guideline [82], which recommends assessing the
effect of drugs on all phases of the reproductive cycle. These recommendations apply to siRNA-
based products. Nevertheless, due to the unique features of these compounds, a case-by-case
approach should be followed for each product, and the requirements for these studies should
be discussed with the competent authorities. The target, indication, chemical modifications,
and systemic bioavailability of the RNAi-based drugs are features that may influence in the
nature of the required studies.
Because the toxicity of siRNAs can be caused by exaggerated pharmacology whenever
reproductive toxicity studies are required, they should be performed in a pharmacologically
active species. Standard reproductive toxicity species in rodents or rabbits can give information
on toxicity related to chemical structure. However, if the compound is not active in these
species or if the biological activity is not deemed to be equivalent to the foreseen activity in
humans, the assessment of reproductive risk may be conducted using an active analog or in a
nonrodent species in which the compound has biological activity. If the former strategy is
chosen, the toxicity and toxicokinetic profile of the surrogate should be taken into account
when interpreting the results. If the compound is only active in NHPs, studies should only be
performed in cases where there is cause for concern. In these particular cases, the number of
animals should be optimized, and a combined enhanced pre-and postnatal developmental
study can be performed as recommended for NBEs. In NHP studies, the assessment of
reproductive toxicology is usually studied by histopathologic examination of the reproductive
organs as part of the general toxicology studies of at least three months. The timing of
reproductive and developmental studies depends on when women of childbearing potential
are to be included in clinical trials. If NHPs are required for the assessment, the timing is more
flexible due to the length and complexity of the studies [83].
5.5. Local tolerance
Local tolerance studies are required for all topically administered drugs. In most cases, the
potential adverse events caused by local tolerance issues are evaluated in the single or
repeated-dose toxicology studies, reducing the number of animals required for the program.
5.6. Safety pharmacology
According to ICH S7A, safety pharmacology studies can be reduced or eliminated for locally
applied products as well as for NBEs that achieve highly specific receptor targeting [84]. For
siRNAs under development for ophthalmology indications, separate safety studies are not
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usually required; instead, functional safety end points are incorporated into the repeated-dose
toxicity studies. If the results of the toxicology studies indicate that there is cause of concern,
separate safety pharmacology studies should be performed.
6. Programs in development and future ahead
Table 1 summarizes the status of siRNA-based therapies under development for ocular
conditions. As mentioned in Section 1, the eye offers multiple advantages for developing
innovative therapies; therefore, studies in the eye pioneered the field of siRNA therapeutics.
The first siRNA to enter clinical development for an ophthalmology indication was bevasiranib
in 2004 shortly followed by sirna-027. Bevasiranib targeted VEGFA, whereas sirna-027 targeted
VEGFR1. These compounds were being developed for the treatment of AMD as both showed
a dose-dependent inhibition of experimental CNV in animal models that correlated with
knockdown of their respective target genes [10, 85]. As mentioned in Section 1, in 2008
Kleinman and coworkers published a study demonstrating that the effect of siRNAs targeting
VEGF and VEGFR on CNV was not mediated by an on-target effect but by activation of TLR3
[12]. The results of these studies indicated that the effect of the compounds on CNV was
sequence-independent and mediated by siRNAs of 21 base pairs or longer. The study also
showed that the internalization of the siRNAs was not required for the inhibition of CNV as
cells of the RPE abundantly express TLR3 on the cytoplasmic surface. The authors used several
sequences, including those of the siRNAs undergoing clinical trials at the time, to point out
that the inhibition of CNV by both bevasiranib and sirna-027 was mediated through an off-
target effect. A subsequent study by the same group showed that activation of TLR3 by IVT
siRNAs led to caspase-3-mediated degeneration of the retinal pigment epithelium (RPE)
questioning the safety of these compounds as therapeutics for back of the eye diseases [13].
The clinical development of bevasiranib was halted in 2007 and of sirna-027 in 2009 both as a
result of not reaching or being unlikely to reach their respective efficacy end points in phase
III trials.
The findings of Kleinman and coworkers boosted research on alternative designs that were
not able to activate TLR3, and as result, a new generation of compounds is currently under‐
going clinical trials. Currently, the most advanced siRNAs-based programs for ocular indica‐
tions are Quark’s QPI-007 and Sylentis’ bamosiran (SYL040012). QPI-007 is a 19-nt modified
siRNA-targeting caspase 2 currently in phase II/III for the treatment of nonarteritic anterior
ischemic optic neuropathy (NAION) [86]. QPI-1007 has shown to be safe when IVT injected to
animal models and humans. The ongoing phase II/III trial for this compound analyzes the
potential of multiple IVT doses to improve visual acuity in patients suffering NAION [87, 88].
Bamosiran is a canonical-designed naked siRNA-targeting β2-adrenergic receptor (ADRB2)
under development for the treatment of increased IOP associated to glaucoma [64, 89–91].
Glaucoma is a degenerative, chronic disease of the optic nerve that can lead to blindness if left
untreated [92]. The mechanistic details of optic nerve degeneration observed in glaucoma are
yet to be fully detailed, but it is well established that reduction of intraocular pressure avoids
RNA Interference260
development of the disease. ADRB2 controls the production and release of aqueous humor.
The aqueous humor is responsible for maintaining optimal IOP. Treatment with topic beta-
blockers has shown to efficiently reduce intraocular pressure, but currently approved beta-
blockers are small molecules and are thus able to reach systemic circulation and systemic
organs were they cause unwanted effects. The rationale behind bamosiran is developing a
locally active compound that efficiently knocks down ADRB2 in the eye but that is not able to
reach systemic tissues reducing the likelihood of side effects. The compound is administered
in eye drops and has been shown to be well tolerated in animal models and humans [64, 93].
Three different doses of bamosiran are currently being studied in an active controlled phase
IIb trial. Previous clinical trials with this compound have shown promising results in healthy
individuals and patients with ocular hypertension [91, 93].
SYL1001 is a naked 19-bp siRNA-targeting transient receptor potential vanilloid-1 (TRPV1) for
the treatment of ocular pain. TRPV1 is a cation channel permeable to calcium activated by heat,
low pH, and capsaicin among other signals. This receptor is present in several structures of
the eye where it has been related, among other roles, to nociception [94]. SYL1001 has shown
to be safe when administered in eye drops to animals and humans and to have analgesic effect
in the capsaicin-induced eye pain model. The compound is currently undergoing a phase I/II
for the treatment of ocular pain associated to dry eye disease, a condition for which no specific
treatment currently exists [89].
PF-655 is a chemically stabilized siRNA-targeting RTP801, a stress-induced adaptor protein
that inhibits mTOR function upstream to TSC1/TSC2 complex in response to a variety of
stresses. Expression of RTP801 is upregulated in response to ischemia, hypoxia, and/or
oxidative stress. Intravitreal injection of PF-655 in preclinical animal models of laser-induced
CNV leads to silencing of RTP801 via a RNAi mechanism without TLR activation and
reduction of CNV volume, vessel leakage, and infiltration of inflammatory cells into the
choroid [95–97]. This compound has undergone phase II clinical trials for the treatment of
diabetic macular edema and wet AMD. Treatment with PF-655 of patients with diabetic
macular edema over a period of 12 months caused a dose-dependent improvement in visual
acuity compared to the visual acuity observed in patients treated with laser photocoagulation
[98]. A subsequent phase IIb trial was conducted with a new set of doses but terminated
because the primary end point was not likely to be achieved. The compound was thereafter
tested in combination with ranibizumab, a monoclonal antibody fragment that targets VEGF
and is the current gold standards for treatment of the disease. The results of this study have
not yet been disclosed. PF-655 has also been studied in patients suffering wet AMD. In this
indication, the compound did not show improvement as a single agent or in combination with
ranibizumab in mean visual acuity after 3 months of dosing.
Self-delivery rxRNAs (sd-rxRNAs) incorporate 2’-F and 2-’O-Me modifications and a sterol
conjugate on the sense strand with the goal of improving stability and cellular uptake. These
compounds have a 19-nt antisense strand and a sense strand usually shorter than 15 nt
resulting in an asymmetric duplex with a phosphorothioated single-stranded tail on the
antisense strand [99]. These compounds have been tested in vitro where they have shown to
be able to induce target knockdown in different cell lines. In vivo analysis of their activity
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showed these compounds are readily taken-up by retinal cells and that the compound is evenly
distributed throughout the mouse retina. Several of these compounds are under development
for different eye conditions and are expected to enter clinical development shortly.
SYL116011 is a naked 19-bp siRNA targeting the calcium release-activated calcium modulator
1 (ORAI1). Store-operated Ca2+ entry (SOCE) is activated in response to depletion of endo‐
plasmic reticulum Ca2+ pools. Activation of SOCE induces Ca2+ entry from extracellular
compartments, and this is mediated by store-operated CRAC channels. CRAC channels are
composed of calcium sensing proteins called STIM (stromal interaction molecule) and pore-
forming subunits named ORAI [100]. Mammalian cells have three ORAI isoforms: ORAI1,
ORAI 2, and ORAI3; although ORAI2 and 3 fulfill the same role as ORAI1, the Ca2+ currents
generated by these proteins are around two- to threefold smaller than the ones generated by
ORAI1 [101]. There is growing evidence that indicates that short-term and long-term activation
of immune cells in allergic responses is mediated by influx of Ca2+ to immune cells from the
extracellular compartment. Short-term responses include the degranulation of mast cells and
the activation of effector cytolitic T cells. Indeed, mast cells lacking either STIM1 or ORAI1
show a considerable defect in degranulation [102, 103]. Long-term responses involve the
modulation of gene expression that controls B and T cell proliferation and differentiation.
SYL116011 is being developed for the treatment of ocular allergies and has shown to reduce
immediate clinical signs in a mouse model of ragweed pollen-induced ocular allergy. The
decrease in clinical signs was accompanied by a reduction in the number of infiltrating
eosinophils in the conjunctiva and reduction of allergy biomarkers.
TT-211 is an AAV‐encapsidated construct that expresses a single shRNA modeled into a
miRNA backbone that inhibits the expression of VEGF‐A for the treatment of wet AMD. VEGF-
a protein is responsible initiating a signaling cascade that stimulates the growth of new blood
vessels, a hallmark of wet AMD. TT-231 is a second-generation candidate designed to express
three shRNAs, which target three different genes, VEGF receptor 2, PDGF-β, and human
complement factor B, proteins that play a major role in the progression of wet AMD. Both these
compounds are yet in a preclinical phase; IND filing is planned for 2017.
STP601 is a multitargeted siRNA cocktail nanoparticle formulation administered by IVT
injection under development for treatment of wet AMD, proliferative diabetic retinopathy,
and herpetic stromal keratitis. The cocktail includes three 25-mer siRNA duplexes targeting
VEGF, VEGFR1, and VEGFR2. Inhibiting this clinically validated pathway at the endothelial
cells lining the interior of the growing blood vessels is thought to halt the progression of AMD.
This product is currently in preclinical stage.
AQA001 is a single-stranded long chain nonmodified ribonucleotide connected by a proline-
derived linker that self-anneals to form a shot-hairpin structure within the molecule. The
compound targeting periostin acts through an RNAi mechanism and is being developed for
the treatment of diabetic retinopathy. The compound has shown positive result in a proof-of-
concept study of CNV [104].
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Name Indication Target Route Sponsor Status
Bevasiranib AMD with choroidal
neovascularization
VEGFA IVT Opko Health Halted in Phase III
Sirna-027 AMD with choroidal
neovascularization
VEGFR1 IVT Allergan Halted in Phase III
QPI-1007 NAION Caspase 2 IVT Quark Active, Phase II/III
Primary Angle Closure
Glaucoma
Active, Phase IIa
PF-655 AMD with choroidal
neovascularization
RTP801 IVT Quark/Pfizer Completed, Phase
II
Diabetic macular oedema Completed, Phase
IIb
SYL040012 Glaucoma β2 ADR Eye Drop Sylentis Completed, Phase
IIb
SYL1001 Ocular pain associated to
dry eye disease
TRPV1 Eye Drop Sylentis Active, Phase IIa
Undisclosed Retinal scaring Undisclosed Intraocular RXi Preclinical
Undisclosed Corneal scaring Undisclosed Eye Drop RXi Preclinical
Undisclosed Macular degeneration Undisclosed Intraocular RXi Preclinical
SYL116011 Ocular allergy ORAI1 Eye Drop Sylentis Preclinical
TT-211 AMD VEGF-A IVT Benitec Preclinical
TT-231 AMD VEGF-A, PDGFβ
and CFB
IVT Benitec Preclinical
STP601 AMD and retinopathy VEGF-VFGFR1-
VEGF2
IVT Sirnaomics Preclinical
AQA001 Diabetic macular oedema Periostin IVT Aqua TherapeuticsPreclinical
Table 1. siRNAs in development for ocular indication.
7. Conclusion
RNA interference is on the verge of becoming a new class of therapeutics [105]. The field of
ophthalmology has played a major role in advancing siRNAs from laboratory tools to the clinic.
In the last few years, significant advances have been made in the understanding of how these
molecules enter and exert its action in the eye and in the identification of the main hurdles that
still need to be addressed. The introduction of chemical modifications as well as the under‐
standing of the immune activation in the eye has significantly improved the pharmaceutical
properties of compounds for eye conditions. However, the following years will tell whether
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improvements on these molecules are enough to be of therapeutic value in the field of
ophthalmology or not.
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